Sanofi’s Rilzabrutinib Meets Primary Endpoint in ITP
Breaking News Demonstrates significantly higher proportion of patients receiving rilzabrutinib achieved primary endpoint of durable platelet response versus placebo. 04.23.24 Sanofi achieved positive results from the LUNA 3 phase 3 study demonstrating that …